Colonia Therapeutics' CEO argues that lentiviral delivery is ideal for oncology's required long-term persistence, while LNP delivery is better suited for autoimmune indications needing transient, multi-dose responses. This frames them as complementary technologies for different therapeutic "swim lanes" rather than as direct rivals in a zero-sum game.

Create's strategy is not limited to a single cell type. They view success in solid tumors as requiring the programming of all immune cells. Their platform can specifically engineer myeloid cells, T-cells, and NK cells in vivo, orchestrating a coordinated, multi-pronged attack on cancer.

Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.

Despite initial hype in oncology where business models struggled, cell therapy is finding a major new application in treating autoimmune diseases. By resetting the immune system, it can offer functional cures for debilitating conditions—a powerful and unexpected pivot for the technology platform.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

Gilead has tightened its criteria for advancing projects, demanding a deep mechanistic understanding before committing significant resources. This involves validating the target, understanding its biological impact preclinically, and identifying biomarkers—moving beyond just a promising hypothesis to a de-risked scientific thesis.

Gilead's acquisition strategy is not monolithic. It differentiates between acquiring foundational, long-duration platforms (like Kite's CAR-T) that kickstart a whole new area of R&D, and acquiring differentiated assets (like Arcelix's BCMA CAR-T) that strengthen an existing therapeutic area with a potentially transformative molecule.

Major players are repurposing oncology's T-cell engager technology for autoimmune diseases. Gilead's $1.675B acquisition of Oral Medicines and Sanofi's $1.05B potential deal with Kali Therapeutics highlight a strategic shift to leverage this powerful modality in a new, high-potential therapeutic area.

The immune system is the initial target for CZI's virtual cell modeling because of its strategic importance. As a mobile system that touches every part of the body, understanding and engineering it offers a powerful lever to address a vast range of conditions, including cancer and autoimmune diseases.